CRISPR 시장 예측(-2031년) : 제공, 용도, 최종사용자, 경쟁, 지역별

The CRISPR market is expected to reach USD 6.12 billion in 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period. Market growth is driven by the increasing adoption of CRISPR-based genome editing in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and molecular diagnostics.

Advancements in base editing, prime editing, RNA editing, and high-fidelity CRISPR systems are further expanding the range of genome-editing applications. Increasing demand for precise, scalable, and reproducible genome-editing workflows is also supporting the adoption of CRISPR products and services.

"The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period"

The CRISPR kits & enzymes segment is expected to grow at the highest CAGR during the forecast period, driven by increasing demand for ready-to-use genome-editing reagents and enzymes across research and genome-engineering workflows. These products support applications such as guide RNA-based editing, gene knockout, gene activation, editing validation, and development of advanced genome-editing systems. Growing adoption of high-throughput screening, functional genomics, and next-generation editors is increasing the need for specialized CRISPR kits and enzymes. Continued development of high-fidelity nucleases, base editors, prime editors, and other engineered editing systems is expected to further support demand for advanced CRISPR products.

"The drug discovery & development segment holds the largest share of the market"

The drug discovery & development segment holds the largest share of the CRISPR market, supported by the increasing use of genome editing for target identification, target validation, disease-model development, functional genomics, and drug screening. Pharmaceutical and biotechnology companies increasingly use CRISPR-based knockout, activation, inhibition, and screening approaches to investigate gene function and disease mechanisms and identify potential therapeutic targets. The growing use of CRISPR in cell and gene therapy development and precision medicine is further supporting demand for genome-editing products, screening platforms, and related services.

"The US is expected to grow at the highest CAGR during the forecast period"

The US is expected to grow at the highest CAGR in the CRISPR market due to its strong presence of leading genome-editing companies, advanced biomedical research infrastructure, and high adoption of CRISPR technologies across research and therapeutic applications. Rising use of CRISPR in drug discovery, functional genomics, cell and gene therapy, genetic disease research, and precision medicine is driving market growth. Technologies such as CRISPR-Cas systems, base editing, prime editing, guide RNA design, and genome-editing screening and validation are increasingly used across pharmaceutical companies, biotechnology firms, academic institutes, and research organizations, further supporting demand.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side - 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio Inc. (Japan), Creative Biogene (US), Fujian SunvBiotech Co., Ltd. (China), EditCR (US), Caribou Biosciences, Inc. (US), Lonza (Switzerland), and Danaher Corporation (US) are some of the key companies offering CRISPR products and services.

Research Coverage

This research report categorizes the CRISPR market by offering (products and services), product type (CRISPR kits & enzymes, CRISPR libraries, and other products), product end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), service type (gRNA synthesis & cell line development, screening & validation, and other services), service end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), application (drug discovery & development, agriculture, and other applications), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the CRISPR market. A comprehensive analysis of key industry players provides insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the CRISPR market. This report also includes a competitive analysis of emerging startups in the CRISPR industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (growing demand for CRISPR-based gene therapies, advancements in CRISPR technology, growing government and private investments and funding for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccines and treatments for genetic diseases, expanding industrial and agricultural applications of CRISPR), and challenges (regulatory hurdles for CRISPR advancements) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and innovations in the CRISPR market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript (US), Takara Bio (Japan), Revvity (US), Danaher (US), and Lonza (Switzerland), among others, for the CRISPR market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN CRISPR MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CRISPR MARKET OVERVIEW
• 3.2 NORTH AMERICA: CRISPR MARKET, BY SERVICE
• 3.3 CRISPR MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 CRISPR MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing demand for CRISPR-based gene therapies
    • 4.2.1.2 Advancements in CRISPR technology
    • 4.2.1.3 Growing government and private investments and funding for CRISPR technology
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Technical challenges associated with CRISPR technology
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Development of new vaccines and treatments for genetic diseases
    • 4.2.3.2 Expanding industrial and agricultural applications of CRISPR
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Regulatory hurdles for CRISPR advancements
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2023-2025
  • 5.5.2 INDICATIVE PRICE TREND FOR CRISPR SERVICES
  • 5.5.3 AVERAGE SELLING PRICE OF CRISPR KITS & REAGENTS, BY REGION, 2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 3822.00)
  • 5.6.2 EXPORT SCENARIO (HS CODE 3822.00)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 CRISPR-CAS9 EDITING DEMONSTRATES DURABLE LIPID REDUCTION
  • 5.10.2 IN VIVO CRISPR EDITING SIGNIFICANTLY REDUCES HEREDITARY ANGIOEDEMA ATTACKS
• 5.11 IMPACT OF 2025 US TARIFFS ON CRISPR MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
    • 5.11.4.4 Rest of the World
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Pharmaceutical & biotech companies
    • 5.11.5.2 Contract Research Organizations (CROs)
    • 5.11.5.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 CRISPR-Cas systems
    • 6.1.1.2 gRNA design & optimization
    • 6.1.1.3 High-throughput CRISPR screening
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Synthetic biology
    • 6.1.2.2 Single-cell genomics
    • 6.1.2.3 Next-generation sequencing
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Stem cell engineering
    • 6.1.3.2 Synthetic DNA & gene synthesis
    • 6.1.3.3 Microfluidics
• 6.2 TECHNOLOGY ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 METHODOLOGY
  • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 6.3.3 LIST OF KEY PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON CRISPR MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 BEST PRACTICES IN AI-ENABLED CRISPR WORKFLOWS
  • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN CRISPR MARKET
  • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
  • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CRISPR TECHNOLOGIES

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
      • 7.1.2.2.1 Germany
      • 7.1.2.2.2 UK
      • 7.1.2.2.3 France
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 Japan
      • 7.1.2.3.2 China
    • 7.1.2.4 Latin America
      • 7.1.2.4.1 Brazil
    • 7.1.2.5 Middle East & Africa
      • 7.1.2.5.1 GCC Countries
      • 7.1.2.5.2 South Africa
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 CRISPR MARKET: BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 CRISPR MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 PRODUCTS
  • 9.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 9.3 SERVICES
  • 9.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

10 CRISPR PRODUCTS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 CRISPR KITS & ENZYMES
  • 10.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
• 10.3 CRISPR LIBRARIES
  • 10.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
• 10.4 OTHER PRODUCTS

11 CRISPR PRODUCTS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
• 11.4 OTHER END USERS

12 CRISPR MARKET, BY SERVICE

• 12.1 INTRODUCTION
  • 12.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
    • 12.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
  • 12.1.2 SCREENING & VALIDATION
    • 12.1.2.1 Rapid advancements in CRISPR technology to drive growth
• 12.2 OTHER SERVICES

13 CRISPR SERVICES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 13.3 ACADEMIC & RESEARCH INSTITUTES
  • 13.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
• 13.4 OTHER END USERS

14 CRISPR MARKET, BY APPLICATION

• 14.1 INTRODUCTION
• 14.2 DRUG DISCOVERY & DEVELOPMENT
  • 14.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
• 14.3 AGRICULTURE
  • 14.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
• 14.4 OTHER APPLICATIONS

15 CRISPR MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth
  • 15.2.2 CANADA
    • 15.2.2.1 Increasing demand for gene-editing technologies to boost growth
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Rapidly increasing biotechnology sector to support growth
  • 15.3.2 UK
    • 15.3.2.1 Significant government investments in genomics research to propel growth
  • 15.3.3 FRANCE
    • 15.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth
  • 15.3.4 ITALY
    • 15.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth
  • 15.3.5 SPAIN
    • 15.3.5.1 Increasing demand for precision medicine to drive growth
  • 15.3.6 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Increasing investments in R&D to drive growth
  • 15.4.2 JAPAN
    • 15.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
  • 15.4.3 INDIA
    • 15.4.3.1 Increasing prevalence of genetic disorders to support growth
  • 15.4.4 AUSTRALIA
    • 15.4.4.1 Growing clinical translation and advancements in CRISPR technologies to support growth
  • 15.4.5 SOUTH KOREA
    • 15.4.5.1 Advancements in next-generation CRISPR and precision RNA editing to support growth
  • 15.4.6 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Growing adoption of genome technologies to propel growth
  • 15.5.2 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 GCC COUNTRIES
    • 15.6.1.1 Saudi Arabia
      • 15.6.1.1.1 Regulatory support and expanding advanced-therapy infrastructure to boost market
    • 15.6.1.2 UAE
      • 15.6.1.2.1 Precision medicine investment and advanced clinical infrastructure to aid market growth
    • 15.6.1.3 Rest of GCC Countries
  • 15.6.2 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 EXPANDING AGRICULTURAL BIOTECHNOLOGY AND GENOMICS RESEARCH TO PROPEL MARKET

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGY/RIGHT TO WIN, JANUARY 2023-SEPTEMBER 2026
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET, JANUARY 2023-SEPTEMBER 2026
• 16.3 REVENUE ANALYSIS, 2021-2025
• 16.4 MARKET SHARE ANALYSIS, 2025
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Product footprint
    • 16.5.5.4 Service footprint
    • 16.5.5.5 Application footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of key startups/SMEs
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.1 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.2 COMPANY VALUATION & FINANCIAL METRICS
• 16.8 BRAND COMPARISON
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 THERMO FISHER SCIENTIFIC INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products & services offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 MERCK KGAA
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products & services offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches
      • 17.1.2.3.2 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 AGILENT TECHNOLOGIES, INC.
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products & services offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Deals
      • 17.1.3.3.2 Expansions
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 GENSCRIPT
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products & services offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Deals
      • 17.1.4.3.2 Expansions
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 REVVITY
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products & services offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product launches
      • 17.1.5.3.2 Deals
  • 17.1.6 LONZA
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products & services offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product launches
      • 17.1.6.3.2 Deals
      • 17.1.6.3.3 Expansions
  • 17.1.7 DANAHER CORPORATION
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products & services offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
      • 17.1.7.3.2 Deals
  • 17.1.8 TAKARA BIO INC.
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products & services offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Deals
  • 17.1.9 CREATIVE BIOGENE
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products & services offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Service launches
  • 17.1.10 FUJIAN SUNYBIOTECH CO., LTD.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products & services offered
  • 17.1.11 EDITCO
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products & services offered
    • 17.1.11.3 Recent financials
      • 17.1.11.3.1 Deals
  • 17.1.12 CARIBOU BIOSCIENCES, INC.
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products & services offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Deals
  • 17.1.13 DEMEETRA AGBIO
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products & services offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Deals
  • 17.1.14 ORIGENE TECHNOLOGIES, INC.
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products & services offered
  • 17.1.15 CELLECTA, INC.
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products & services offered
• 17.2 OTHER PLAYERS
  • 17.2.1 MAMMOTH BIOSCIENCES, INC.
  • 17.2.2 APPLIED STEMCELL
  • 17.2.3 NEW ENGLAND BIOLABS
  • 17.2.4 TOOLGEN, INC.
  • 17.2.5 GENECOPOEIA, INC.
  • 17.2.6 TWIST BIOSCIENCE
  • 17.2.7 SYNTHEGO
  • 17.2.8 EGENESIS
  • 17.2.9 MANUS BIO
  • 17.2.10 PRECISION BIOSCIENCES

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH DATA
  • 18.1.1 SECONDARY DATA
  • 18.1.2 PRIMARY RESEARCH
• 18.2 MARKET SIZE ESTIMATION
  • 18.2.1 GLOBAL MARKET ESTIMATION
    • 18.2.1.1 Insights from primary experts
  • 18.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 18.3 MARKET GROWTH RATE PROJECTION
• 18.4 DATA TRIANGULATION
• 18.5 RESEARCH ASSUMPTIONS
• 18.6 RESEARCH LIMITATIONS
• 18.7 RISK ANALYSIS

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 CUSTOMIZATION OPTIONS
• 19.4 RELATED REPORTS
• 19.5 AUTHOR DETAILS